Paper of the MonthFeatured Slider
Paper of the month: Edaravone reduces disability progression in early ALS
or August 2017, we have selected: The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505-512.
There is evidence that oxidative stress induced by free radicals is a key factor of progression in amyotrophic lateral sclerosis (ALS).










by Anna Sauerbier
Neuroscience-based Nomenclature
Memories from the 3rd EAN Congress in Amsterdam
find yourself, a colleague or a friend in the
Amsterdam photo-gallery
Amsterdam 2017: Memories from the 3rd EAN Congress – view the photo gallery was last modified: July 31st,…
by Antonella Macerollo
Dear Readers,
An interesting interactive case has been published in eBrain this month. It has been written by the neurology, radiology and neurosurgery teams from Belgrade, Serbia. Please, find below the abstract.
To see the full…